ABSTRACT: Optimization of a series of R132H IDH1 inhibitors from a high throughput screen led to the first potent molecules that show robust tumor 2-HG inhibition in a xenograft model. Compound 35 shows good potency in the U87 R132H cell based assay and ∼90% tumor 2-HG inhibition in the corresponding mouse xenograft model following BID dosing. The magnitude and duration of tumor 2-HG inhibition correlates with free plasma concentration.
T he family of isocitrate dehydrogenases (IDHs) includes two NADP dependent isoforms IDH1 and IDH2, which catalyze the oxidative decarboxylation of isocitrate to produce carbon dioxide, α-ketoglutarate (α-KG), and NADPH. 1, 2, 14 The implication of a role for IDH in cancer was revealed after somatic mutations in IDH1 were identified through a genome wide mutation analysis in glioblastoma. 3 This landmark study was followed by high throughput sequencing, which revealed the presence of mutations in IDH1 in more than 70% of grade II−III gliomas and secondary glioblastomas, 4 as well as in approximately 10−15% of patients with acute myeloid leukemia (AML). 5 These somatic mutations were found at a key arginine residue belonging to the catalytic triad found in the enzyme's active site (R132 for IDH1). This active site mutation results in loss-of-function for the oxidative decarboxylation of isocitrate and confers a novel gain-of-function for the production of the oncometabolite D-2-hydroxyglutarate (2-HG). 6 Further characterization of the mutation showed that overexpression of mutant IDH1 in U87-MG, a human glioblastoma cell line, resulted in 100-fold elevated levels of 2-HG relative to the same cells expressing vector alone (data not shown). 6 Recently, it was demonstrated that 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including histone and DNA demethylases, 7, 8 and several studies have shown that 2-HG producing IDH mutants are involved in global histone and DNA methylation alterations which may contribute to tumorigenesis through epigenetic rewiring. 9, 10 Taken together, these findings implicate mutant IDH1 as an oncogene and a compelling drug target for new therapies for glioma and AML patients.
In order to identify small molecule inhibitors of IDH1, 11, 12 we conducted a high-throughput screening (HTS) campaign against R132H IDH1 mutant protein homodimer. Library screen followed by confirmation of the active hits provided phenyl-glycine inhibitor 1. Detailed kinetic mechanism-ofaction studies showed compound 1 binding to be reversible and behaving as competitive inhibitor with respect to α-KG and uncompetitive with respect to NADPH (data not shown). Given its attractive chemical structure and well-defined inhibitory properties, we selected this compound as a starting point for further optimization.
We report herein that optimization of 1 led to the identification of 35, the first reported R132H IDH1 inhibitor to show robust in vivo reduction of 2-HG levels in a tumor xenograft model.
The phenyl-glycine scaffold was readily assembled via four component Ugi reaction, 13 as depicted retrosynthetically in Figure 1 . Compound 1 was synthesized using cyclopentyl isocyanide, o-methyl benzaldehyde, m-fluoroaniline, and (2-thiophen-2-yl) acetic acid as starting materials. If 2-chloroacetic acid is used for the Ugi acid component, intermediate 2 (R 4 = Cl) is readily obtained and can be used for further functionalization at R 4 through nucleophilic displacement of the chlorine.
Upon identification of 1 as a screening hit, we set out to understand the key structural elements that were responsible for the binding affinity of this compound to the R132H IDH1 protein ( Figure 2 ). The molecule displays mostly hydrophobic features, with three aromatic rings positioned around two amide carbonyl groups, with a rather high clogP (5.6). Starting from a closely related analog 3 (IC 50 = 0.08 μM), we first initiated a substitution pattern investigation of the phenylglycine backbone. The eutomer/distomer relationship of the α-carbon stereocenter was established by chiral synthesis of analog 3 starting from D-and L-mandelic acid, 14 which provided 4 (S) and 5 (R) enantiomers, respectively, with compound 4 (IC 50 = 0.06 μM) possessing essentially all of the activity found in the racemate. The enantiospecificity of this enzyme inhibition held true in many analogs subsequently investigated (data not shown).
For rapid exploration of structure−activity relationships (SARs), all subsequent compounds were profiled in their racemic form. Geminal substitution at the α-carbon as depicted for 6 incurred an 18-fold potency loss compared to the case of 3. Next, alkylation of the secondary amide nitrogen as shown for 7 caused a 45-fold loss in potency compared to the case of 3, while replacement of either the C-terminus or N-terminus carbonyl groups (compounds 8 and 9) with a CH 2 moiety resulted in significant loss of biochemical activity, highlighting the importance of both amide moieties for binding affinity.
We then started a systematic investigation of SAR for the Nand C-terminus regions of the scaffold, as well as the central aromatic moieties, with a key objective to improve properties, including decreasing the lipophilicity of the initial hit 1, while improving biochemical potency. R 1 functional group exploration (Table 1) revealed that carbocycles were well tolerated, with cyclohexyl 10 slightly better (IC 50 = 0.05 μM) than the starting HTS hit 1. As the ring size decreased from cyclohexyl 10 to cyclopropyl 13, potency decreased gradually to low micromolar values. Replacement of cyclohexyl with aromatic rings (o-tolyl, benzyl) as shown for 14 and 15 led to a 10−30-fold decrease in biochemical potency compared to the case of 10. In an attempt to improve the properties of these compounds by decreasing the clogP through heteroatom substitution in the cyclohexyl ring, we found that pyran 16 was 10-fold less potent than 10, while piperidine 17 suffered a nearly 100-fold loss of biochemical potency. Evaluation of R 2 substituents revealed that for the α-aromatic ring ortho-substitution was most favored, while replacement of the phenyl group with heterocycles or carbocycles afforded only low micromolar potency analogs.
14 A preliminary survey of R 3 pointed to meta-substituted aromatic groups being most favorable, while aliphatic moieties, acyclic or cyclic, or heteroatom containing carbocycles provided analogs with a significant drop in biochemical potency. 14 These observations coupled with the C-terminus amide SAR results shown in Table  1 suggested that the phenyl-glycine scaffold was binding in a highly lipophilic region of the enzyme.
Having elucidated SAR on three areas of the scaffold, we continued our exploration on the N-terminus R 4 substituents in an additional approach to improve the compound physical chemical properties and decrease the overall lipophilicity of the original hit. Synthetic chemistry readily amenable to parallel arrays allowed us to rapidly explore a variety of functional groups at the N-terminus ( Table 2) . (Figure 1) . Replacement of chlorine in compound 22 with amino group in analog 23 caused a potency drop from 0.9 to 7.8 μM. A small set of cycloalkyl amines with an adjustment of ring size led to diminishing biochemical potency from cyclopropyl 24 (0.19 μM) to cyclohexyl 26 (1.27 μM). Interestingly, when the cyclohexyl group in 26 was replaced by a phenyl ring in compound 27, biochemical potency was substantially enhanced from 1.27 μM to 0.06 μM. Alkylation of the aniline nitrogen as shown in analog 28 maintained the potency at 0.05 μM. Use of aromatic rings for R 4 did improve the potency compared to the aliphatic analogs (24−26); however, clogP increased as well, retaining their highly hydrophobic character. Encouraged by the good potency of aromatic tertiary amine 28, we next tested a small set of tertiary aliphatic amines, with the aim of decreasing the lipophilicity of the scaffold by introduction of basic solubilizing groups. Among the examples that were evaluated, morpholine 30 displayed the best biochemical potency (0.24 μM), while pyrrolidine 29 and piperazine 31 afforded weakly active single digit micromolar analogs. Addition of a fused phenyl ring to pyrrolidine as shown in 32 improved the potency by 10-fold at the expense of an a The IC50 values for R132H and R132C and wt homodimers are the mean of at least two determinations performed as described in the Supporting Information. b For compounds with less than 100% enzyme inhibition, the maximum inhibition achieved is shown. 4 -substitution allowed introduction of a diverse set of substituents that were well tolerated, possibly indicating that this part of the phenyl glycine scaffold may be binding in a solvent exposed area of the protein.
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As the SAR investigation revealed functional group modifications that provided potent inhibitors in the R132H enzymatic assay, we selected a focused set of analogs for evaluation against R132C IDH1 mutant 15 and wild-type IDH1 enzymes. Additionally, compounds were profiled in the glioblastoma U87 cells that overexpress mutant R132H IDH1, as well as the HT1080 chondrosarcoma cell line, which expresses the endogenous R132C IDH1 mutant. 16 These cell lines produce significant levels of 2-HG compared to vector cells alone. Upon treatment with inhibitor for 48 h, the levels of 2-HG were measured in the media by LCMS, to generate IC 50 values.
14 Within the same experiment, 50% growth inhibition (GI 50 ) was determined by measuring total cellular ATP after 72 h of compound treatment.
As shown in Table 3 , the majority of compounds showed similar biochemical potency against the R132C IDH1 mutant and displayed cellular IC 50 values less than 0.5 μM in both U87 and HT1080 cell lines, with a 3−5-fold shift in enzyme to cell potency in most cases. Exquisite selectivity for R132H and R132C IDH1 mutant isoforms was demonstrated by the poor biochemical activity against the wild-type IDH1 and the lack of induction of nonspecific cell death (GI 50 > 20 μM).
Compound 35, equipotent in both enzyme R132H and U87 cellular assays, was selected for additional in vivo profiling in the U87 R132H tumor xenograft mouse model (Figure 3) . In vitro and in vivo DMPK studies were conducted for compound 35. This analog showed rapid turnover in human and rat microsomal incubations with an estimated hepatic extraction ratio of 0.93 and 0.85, respectively. Plasma protein binding was 95.7% in mouse using the equilibrium dialysis method. Reasonable plasma exposure was achieved via intraperitoneal dosing at 50 mg/kg (AUC 0−24h = 20800 h·ng/mL), enabling the use of inhibitor 35 for further in vivo studies. Female nude mice bearing U87 R132H tumor xenografts 14 were dosed via IP route with 150 mg/kg of 35 formulated in 0.5% MC and 0.2% Tween 80, and then they were compared to the vehicle control animals. Blood and tumor samples were taken at different time points following compound administration. The plasma and tumor concentrations of inhibitor 35, as well as the corresponding tumor 2-HG concentrations were determined using sensitive and specific LC/MS/MS methods. The unbound plasma concentration of 35 was calculated using the total plasma concentration of 35 and free fraction of 35 in mouse plasma (4.3%).
Following a single dose of 35, the estimated plasma free concentration of 35 was higher than the in vitro cellular IC 50 value (0.07 μM) for over 10 h. The magnitude and duration of tumor 2-HG inhibition correlated well with the free plasma concentration of 35. Compared to a single dose, a repeat dose of 35 provided longer exposure coverage time (drug exposure > IC 50 ) while the C max of 35 was similar following single and BID dosing. Better tumor 2-HG inhibition was achieved following BID dosing compared to a single dose, where the maximum tumor 2-HG inhibition was 89.4% and 69%, respectively. These results demonstrated that tumor 2-HG inhibition correlated with the duration of drug exposure and that robust tumor 2-HG inhibition is achievable with adequate and sustainable drug exposure.
In conclusion, we have discovered the first class of potent IDH1 mutant inhibitors through optimization of HTS hits. Compound 35 is a potent inhibitor of 2-HG production in U87 R132H cells and shows ∼90% tumor 2-HG inhibition in vivo following three BID doses. As high levels of 2-HG have been shown to alter the epigenetic state and biology of cells, 9,10,17 the utility of this molecule will be important to assess the biological consequences of IDH mutations and the potential of IDH inhibitors for treating IDH mutant tumors.
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